EUVIMEDEUVIMED entdecken
Open Access

Age is a significant biomarker for the selection of neoadjuvant chemotherapy plus radiotherapy versus concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma

Yihong Lin, Xiongbin Yu, Linbin Lu, Hong Chen, Junxian Wu, Yaying Chen, Qin Lin, Xuewen Wang, Xi Chen, Xiong Chen

Cancer Biomarkers · 2023

DOI: 10.3233/cbm-210357 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Biomarkers, 2023. Verfasst von Yihong Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Nasopharyngeal Neoplasms, Carcinoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The optimal timing of combined chemotherapy with radiotherapy for locally advanced nasopharyngeal carcinoma (LA-NPC) is undetermined. OBJECTIVE: This study aimed to compare the therapeutic efficacy of neoadjuvant chemotherapy (NACT) followed by radiotherapy (RT) and concurrent chemoradiotherapy (CCRT). METHODS: Five hundred and thirty-eight patients diagnosed with LA-NPC and treated with NACT + RT or CCRT alone were enrolled in the study. Restricted cubic spline regression (RCS) was used to determine the relationship between age and the hazard Ratio of death. A Kaplan-Meier analysis was performed to evaluate overall survival (OS) related to NACT + RT or CCRT alone. Cox proportional hazards models were used to adjust for potential confounding factors. RESULTS: Compared with the CCRT alone regimen, the NACT + RT regimen showed a significantly better OS rate with a 62% decreased risk of death in a subgroup of patients aged ⩾ 45 years (hazard ratio, HR: 0.38; 95% confidence interval, CI: 0.24–0.61). In patients aged < 45 years, the risk of death was significantly increased when NACT + RT was chosen compared with CCRT (HR: 4.10; 95% CI: 2.09–8.07). CONCLUSIONS: Age is a significant biomarker when selecting NACT + RT or CCRT alone in patients with locally advanced NPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nasopharyngeal NeoplasmsCarcinomaHumansNasopharyngeal CarcinomaNeoadjuvant TherapyTreatment OutcomeChemoradiotherapyAntineoplastic Combined Chemotherapy ProtocolsBiomarkersRetrospective Studies

Stichwörter der Autor:innen

Nasopharyngeal carcinomaageconcurrent chemoradiotherapyneoadjuvant chemotherapyradiotherapy

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China.
  • Fudan University Shanghai Cancer Center (Xiamen), Xianmen, Fujian, China.
  • Department of Oncology, Fuqing Hospital of Fujian Province, The Affiliated Fuqing Hospital to Fujian Medical University, Fuqing, Fujian, China.
  • Department of Oncology, The 900th Hospital of the People's Liberation Army Joint Service Support Force, Fuzong Clinical Medical College of Fujian Medical University, Fuzhou, Fujian, China.

Zitieren

APA

Lin, Y., Yu, X., Lu, L., Chen, H., Wu, J., Chen, Y., Lin, Q., Wang, X., Chen, X., & Chen, X. (2023). Age is a significant biomarker for the selection of neoadjuvant chemotherapy plus radiotherapy versus concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma. Cancer Biomarkers. https://doi.org/10.3233/cbm-210357

Vancouver

Lin Y, Yu X, Lu L, Chen H, Wu J, Chen Y, et al. Age is a significant biomarker for the selection of neoadjuvant chemotherapy plus radiotherapy versus concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma. Cancer Biomarkers. 2023. doi:10.3233/cbm-210357

BibTeX
@article{Lin2023,
  author = {Lin, Yihong and Yu, Xiongbin and Lu, Linbin and Chen, Hong and Wu, Junxian and Chen, Yaying and Lin, Qin and Wang, Xuewen and Chen, Xi and Chen, Xiong},
  title = {Age is a significant biomarker for the selection of neoadjuvant chemotherapy plus radiotherapy versus concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma},
  journal = {Cancer Biomarkers},
  year = {2023},
  doi = {10.3233/cbm-210357}
}
Kostenlos starten →